Antimicrobial resistance is a major challenge in the treatment of bacterial infections. One mechanism responsible for resistance is the production of beta-lactamase enzymes, which can break down certain beta-lactam antibiotics before they effectively act on bacteria.
Avibactam is a non-beta-lactam beta-lactamase inhibitor developed to inhibit several clinically important beta-lactamase enzymes. Understanding the avibactam mechanism of action helps explain why it is combined with selected antibiotics and how these combinations may address particular bacterial resistance mechanisms.
What Is Avibactam?
Avibactam is a diazabicyclooctane (DBO) beta-lactamase inhibitor. Unlike conventional beta-lactam antibiotics, it does not primarily work by disrupting bacterial cell-wall synthesis.
Instead, avibactam inhibits certain beta-lactamase enzymes that bacteria produce to protect themselves against beta-lactam antibiotics.
Avibactam is used in combination with selected antibiotics. Its role is to inhibit susceptible enzymes that would otherwise degrade the partner antibiotic, helping preserve that antibiotic’s activity against susceptible bacteria.
Avibactam does not work against every beta-lactamase, and its effect depends on the enzyme involved and the antibiotic combination being used.
How Does Avibactam Work?
The mechanism of action of avibactam involves the inhibition of susceptible beta-lactamase enzymes.
1. Recognition of Beta-Lactamase Enzymes
Beta-lactamases are bacterial enzymes that can hydrolyze the beta-lactam ring found in many antibiotics. Once an antibiotic is hydrolyzed, its antibacterial activity may be reduced or lost.
Avibactam interacts with susceptible beta-lactamases, including many enzymes belonging to classes A and C and certain class D enzymes.
2. Formation of a Reversible Covalent Complex
Avibactam binds to susceptible beta-lactamases through a covalent interaction involving the enzyme’s active site.
Unlike conventional beta-lactam substrates that are hydrolyzed and released, avibactam can form a reversible covalent complex with susceptible enzymes. The inhibitor can subsequently dissociate, allowing it to inhibit enzyme activity through a mechanism that differs from the irreversible breakdown of many beta-lactam antibiotics.
This interaction reduces the ability of the inhibited enzyme to hydrolyze its susceptible antibiotic substrates.
3. Protection of the Partner Antibiotic
When avibactam inhibits susceptible beta-lactamases, it can help protect a partner antibiotic from enzymatic degradation.
This does not mean avibactam independently kills bacteria or restores susceptibility in every resistant organism. Rather, its function is to inhibit particular resistance enzymes so that the partner antibiotic may remain active when the organism is susceptible to the combination.
Which Beta-Lactamases Can Avibactam Inhibit?
Avibactam inhibits several important groups of beta-lactamases.
Class A Beta-Lactamases
This group includes many extended-spectrum beta-lactamases (ESBLs) and certain carbapenemases, such as KPC enzymes.
These enzymes can compromise the activity of multiple beta-lactam antibiotics. Avibactam can inhibit many enzymes within this class.
Class C Beta-Lactamases
Class C enzymes include AmpC-type beta-lactamases, which may contribute to resistance in several Gram-negative bacterial species.
Avibactam inhibits many class C beta-lactamases, potentially helping protect an appropriate partner antibiotic.
Certain Class D Beta-Lactamases
Some class D enzymes, including certain OXA-type enzymes, can also be inhibited by avibactam. However, inhibition varies among individual enzymes, so activity against one enzyme should not be assumed to apply to every class D beta-lactamase.
What About Metallo-Beta-Lactamases?
Avibactam does not directly inhibit metallo-beta-lactamases (MBLs), such as NDM, VIM, and IMP.
This distinction is important when interpreting antibiotic resistance. A bacterium may produce an MBL alongside other beta-lactamases that avibactam can inhibit.
In the aztreonam-avibactam combination, aztreonam is generally stable against hydrolysis by MBLs, while avibactam inhibits certain accompanying serine beta-lactamases that might otherwise degrade aztreonam.
The combination’s activity still depends on the organism’s overall resistance profile and susceptibility.
Why Is Avibactam Combined With Aztreonam?
Aztreonam is a monobactam antibiotic that interferes with bacterial cell-wall synthesis. It is generally not hydrolyzed by MBL enzymes, but other beta-lactamases produced by the same bacterium may compromise its activity.
Avibactam can inhibit certain of these accompanying enzymes. This complementary mechanism provides the scientific rationale for combining aztreonam and avibactam when targeting susceptible bacteria with complex beta-lactam resistance mechanisms.
For readers interested in the associated pharmaceutical product, Meblanios by AIONIOS Pharma has a dedicated product page containing product information. Always consult verified prescribing information for the precise composition, approved indications, and safety details.
Avibactam Compared With Traditional Beta-Lactamase Inhibitors
Beta-lactamase inhibitors differ in chemical structure, enzyme activity, and the antibiotics with which they are used.
Avibactam belongs to the diazabicyclooctane group and differs structurally from older inhibitors such as clavulanic acid, sulbactam, and tazobactam.
Its activity against many class A and class C enzymes, along with certain class D enzymes, is one reason it is important in modern beta-lactam combination development.
However, no beta-lactamase inhibitor covers every resistance mechanism. The appropriate antibiotic combination depends on the organism, its susceptibility profile, the infection, and current clinical guidance.
Clinical Importance of Understanding Avibactam’s Mechanism
Understanding the avibactam mechanism of action is useful for interpreting laboratory susceptibility results and the scientific rationale behind antibiotic combinations.
Important considerations include:
- Identifying the beta-lactamase enzymes produced by the bacterium.
- Understanding which enzymes avibactam can inhibit.
- Recognizing that avibactam does not directly inhibit MBL enzymes.
- Evaluating the activity of the complete antibiotic combination rather than the inhibitor alone.
- Using validated susceptibility testing and current clinical guidance when selecting treatment.
Antimicrobial stewardship remains essential to help preserve the effectiveness of available antibiotics and reduce the spread of resistance.
Frequently Asked Questions
What is the main mechanism of action of avibactam?
Avibactam inhibits susceptible beta-lactamase enzymes by forming a reversible covalent complex with the enzyme. This reduces enzymatic degradation of a susceptible partner antibiotic.
Does avibactam kill bacteria directly?
Avibactam is primarily a beta-lactamase inhibitor, not a standalone antibacterial agent. Its role is to protect the activity of a partner antibiotic against susceptible beta-lactamases.
Does avibactam inhibit NDM enzymes?
No. NDM is a metallo-beta-lactamase, and avibactam does not directly inhibit this enzyme class.
Why is avibactam combined with aztreonam?
Aztreonam is generally stable against MBL-mediated hydrolysis, while avibactam can inhibit certain other beta-lactamases that may otherwise compromise aztreonam’s activity.
Where can I find information about Meblanios?
Visit the Meblanios product page on AIONIOS Pharma for the available product information. Refer to verified product documentation for approved uses and safety information.
Conclusion
Avibactam is an important beta-lactamase inhibitor that works by reversibly inhibiting several clinically significant enzyme groups. By reducing the activity of susceptible beta-lactamases, it can help preserve the effectiveness of a partner antibiotic against susceptible bacteria.
Its role in combination with aztreonam illustrates how understanding bacterial resistance mechanisms can guide antibiotic development. However, avibactam does not inhibit all beta-lactamases, and the effectiveness of any antibiotic combination must be evaluated in the context of the specific organism, susceptibility results, and appropriate clinical guidance.